Oncternal Therapeutics (ONCT) to Release Quarterly Earnings on Thursday

Oncternal Therapeutics (NASDAQ:ONCT) will be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.17 million. Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. During the same period last year, the firm earned ($4.00) EPS. On average, analysts expect Oncternal Therapeutics to post $-11 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Oncternal Therapeutics Stock Up 2.9 %

ONCT stock traded up $0.26 during trading hours on Tuesday, hitting $9.00. 3,481 shares of the stock were exchanged, compared to its average volume of 5,923. Oncternal Therapeutics has a 12 month low of $5.57 and a 12 month high of $13.14. The company has a 50-day simple moving average of $8.78 and a two-hundred day simple moving average of $8.36.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ONCT shares. StockNews.com started coverage on Oncternal Therapeutics in a research report on Friday. They set a “hold” rating on the stock. HC Wainwright dropped their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th.

Insider Buying and Selling

In related news, Director Robert James Wills purchased 6,914 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was bought at an average price of $8.48 per share, for a total transaction of $58,630.72. Following the completion of the transaction, the director now owns 6,914 shares in the company, valued at approximately $58,630.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have purchased 10,714 shares of company stock valued at $92,736. 8.00% of the stock is owned by company insiders.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.